KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Discontinued OperationsCash from Discontinued OperationsCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Amortization of Deferred Charges (2018 - 2022)

TherapeuticsMD filings provide 8 years of Amortization of Deferred Charges readings, the most recent being $2.6 million for Q3 2022.

  • On a quarterly basis, Amortization of Deferred Charges rose 74.81% to $2.6 million in Q3 2022 year-over-year; TTM through Sep 2022 was $21.1 million, a 317.92% increase, with the full-year FY2021 number at $5.7 million, up 124.68% from a year prior.
  • Amortization of Deferred Charges hit $2.6 million in Q3 2022 for TherapeuticsMD, down from $7.9 million in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $9.0 million in Q1 2022 to a low of $119753.0 in Q3 2018.
  • Median Amortization of Deferred Charges over the past 5 years was $887000.0 (2020), compared with a mean of $1.7 million.
  • Biggest five-year swings in Amortization of Deferred Charges: soared 54.98% in 2021 and later surged 611.32% in 2022.
  • TherapeuticsMD's Amortization of Deferred Charges stood at $119950.0 in 2018, then skyrocketed by 127.74% to $273171.0 in 2019, then surged by 224.71% to $887000.0 in 2020, then soared by 72.6% to $1.5 million in 2021, then skyrocketed by 68.65% to $2.6 million in 2022.
  • The last three reported values for Amortization of Deferred Charges were $2.6 million (Q3 2022), $7.9 million (Q2 2022), and $9.0 million (Q1 2022) per Business Quant data.